NUVBNuvation Bio Inc.Running, no new patients
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Non Small Cell Lung Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jun 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 217 (final count)
- Started
- Sep 1, 2021
- Main results expected
- Jun 11, 2025
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR) by independent radiology review committee (IRC)
Measured over: Up to 4 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-06-11, no fading
Raw record changes
- none yet
Trial ID NCT04919811 · record last updated 2026-01-07 · checked 2026-11-09 15:47 UTC